|
May 2
|
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
|
|
Apr 25
|
MindMed to Present at Upcoming May Medical Conferences
|
|
Apr 2
|
MindMed to Present at Upcoming April Medical Conferences
|
|
Apr 1
|
MindMed Announces Voluntary Delisting from Cboe Canada
|
|
Mar 11
|
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
|
|
Mar 10
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Mar 7
|
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
|
|
Mar 7
|
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
|
|
Feb 22
|
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
|
|
Feb 7
|
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
|
|
Nov 2
|
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
|
|
May 2
|
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
|
|
May 1
|
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
|